{"id":389033,"date":"2024-11-14T00:00:00","date_gmt":"2024-11-14T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0001-2024-biopharma-breast-cancer-disease-landscape-forecast-g7-2024\/"},"modified":"2026-03-31T10:27:56","modified_gmt":"2026-03-31T10:27:56","slug":"dlsfon0001-2024-biopharma-breast-cancer-disease-landscape-forecast-g7-2024","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0001-2024-biopharma-breast-cancer-disease-landscape-forecast-g7-2024\/","title":{"rendered":"Breast Cancer | Disease Landscape &#038; Forecast | G7 | 2024"},"content":{"rendered":"<p>CDK4\/6 inhibitors (Pfizer\u2019s Ibrance, Novartis\u2019s Kisqali, and Eli Lilly\u2019s Verzenio\/Verzenios) combined with endocrine therapy are central to the treatment of metastatic hormone receptor-positive \/ HER2-negative breast cancer and are expected to drive robust sales in the early-stage setting as well. Novel biomarker-driven therapies (i.e., Novartis\u2019s Piqray, AstraZeneca\u2019s Truqap, and Menarini\u2019s Orserdu) gained approval recently, and the market is set to become increasingly crowded with agents that seek to overcome endocrine resistance. The treatment of HER2-positive breast cancer is rapidly evolving owing to the approval and forecast label expansions of agents such as Enhertu (Daiichi Sankyo \/ AstraZeneca), which has become a key therapy for the newly defined HER2-low subgroup. In triple-negative breast cancer, the use of immune checkpoint inhibitors (Merck &#038; Co.\u2019s Keytruda) is standard, and TROP2-targeted agents (Gilead\u2019s Trodelvy)\u2014currently used in the pretreated metastatic setting\u2014are expected to move to the more-lucrative earlier lines of treatment.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>How large are the clinically and commercially relevant drug-treatable breast cancer populations?<\/li>\n<li>What is the expected market impact of recent drug approvals, such as Piqray, Orserdu, Truqap, and Enhertu, on the various subpopulations of breast cancer?<\/li>\n<li>Which are the most promising agents in the pipeline, and how will they shape the future of this therapy market?<\/li>\n<li>What key drivers and constraints will affect the breast cancer therapy market over the forecast period?<\/li>\n<\/ul>\n<p><strong>G<\/strong><strong><strong>eography<\/strong>:<\/strong> United States, EU5, Japan<\/p>\n<p><strong>Primary research:<\/strong> 19 country-specific interviews with thought-leading medical oncologists and supported by survey data collected for this and other Clarivate research<\/p>\n<p><strong>Epidemiology:<\/strong> Incidence of breast cancer by country; drug-treatable \/ drug-treated cases segmented by hormone receptor and HER2 status, stage, menopausal status, and line of therapy<\/p>\n<p><strong>Forecast:<\/strong> 10-year, annualized, drug-level sales and patient share of key breast cancer therapies through 2033, segmented by brands and epidemiological subpopulations<\/p>\n<p><strong>Drug treatments:<\/strong> Coverage of select current and emerging therapies<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Key features<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n<p>Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389033","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-breast-cancer","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389033","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389033\/revisions"}],"predecessor-version":[{"id":575889,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389033\/revisions\/575889"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389033"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}